论文部分内容阅读
[目的]观察健脾疏肝颗粒对高脂饲料诱导的非酒精性脂肪性肝炎大鼠的影响,探讨其防治机制。[方法]98只SD大鼠,随机分为空白组、模型组、三七脂肝丸组(1.5g/kg)、易善复组(0.1368g/kg)、健脾疏肝颗粒高、中、低剂量组(18.6g、9.3g、4.7g生药/kg),每组14只。除空白组以标准饲料喂养外,其余各组喂饲高脂饲料,8周后进行给药治疗,给药容积1ml/kg,1次/d。12周后处死大鼠,检测大鼠血清ALT、AST、TC、TG、ALP水平,肝匀浆TC、TG、MDA、SOD、GSH-PX水平。[结果]与模型组比较,健脾疏肝颗粒高剂量组大鼠血清ALT含量显著降低(P<0.05);中剂量组大鼠血清AST、ALP含量显著降低(P<0.05;P<0.05);高、中、低剂量组大鼠血清TG(P<0.05,0.05,0.01),肝匀浆TC(P<0.05,0.01,0.01)、TG(P<0.05,0.05,0.05)、MDA(P<0.01,0.01,0.01)含量均显著降低;中、低剂量组大鼠肝脏SOD含量升高明显(P<0.05,0.01);高、中剂量组大鼠肝脏GSH-PX含量显著升高(P<0.01,0.01);高、中、低剂量组大鼠血清TC含量(P>0.05,0.05,0.05)有降低趋势。[结论]健脾疏肝颗粒可有效防治非酒精性脂肪性肝炎,其机理可能与降低相关酶的活力,提高抗脂质过氧化能力有关。
[Objective] To observe the effect of Jianpi Shugan granule on non-alcoholic steatohepatitis induced by high-fat diet and to explore the mechanism of its prevention and treatment. [Method] 98 SD rats were randomly divided into blank group, model group, Sanqizhigan Pill group (1.5g / kg), Yi Shan Fu group (0.1368g / kg) , Low dose group (18.6g, 9.3g, 4.7g crude drug / kg), 14 in each group. In addition to the blank group fed with standard feed, the remaining groups were fed high-fat diet, 8 weeks after the treatment, the administration volume 1ml / kg, 1 time / d. After 12 weeks, the rats were sacrificed and the levels of ALT, AST, TC, TG, ALP, TC, TG, MDA, SOD and GSH-PX in the liver homogenates were measured. [Results] Compared with the model group, the serum ALT level in the Jianpi Shugan Granules high-dose group was significantly lower (P <0.05); the serum AST and ALP levels were significantly lower in the middle-dose group (P <0.05; P <0.05) (P <0.05, 0.05, 0.01), liver homogenate TC (P <0.05,0.01,0.01), TG <0.01, 0.01, 0.01). The levels of SOD in the liver of middle and low dose groups were significantly increased (P <0.05, 0.01), while the levels of GSH-PX in liver of high and middle dose groups were significantly increased <0.01, 0.01). The levels of TC in serum of high, medium and low dose groups decreased (P> 0.05, 0.05, 0.05). [Conclusion] Jianpi Shugan Granule can effectively prevent and treat nonalcoholic steatohepatitis. The mechanism may be related to reducing the activity of related enzymes and improving the anti-lipid peroxidation ability.